Home › Compare › SRAX vs JNJ

SRAX vs JNJ: Dividend Comparison 2026

SRAX yields 200000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRAX wins by $4.911780474428384e+29M in total portfolio value
10 years
SRAX
SRAX
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full SRAX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SRAX vs JNJ

📍 SRAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRAXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRAX + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SRAX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRAX
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, SRAX beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRAX + JNJ for your $10,000?

SRAX: 50%JNJ: 50%
100% JNJ50/50100% SRAX
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SRAX
Analyst Ratings
5
Buy
Consensus: Buy
Price Target
$6.00
+599900.0% upside vs current
Range: $6.00 — $6.00
Altman Z
-9.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRAX buys
0
JNJ buys
0
No recent congressional trades found for SRAX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRAXJNJ
Forward yield200000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.911780474428384e+29M$20.0K ✓
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.911464459982279e+29M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$6.00$228.73 ✓

Year-by-year: SRAX vs JNJ ($10,000, DRIP)

YearSRAX PortfolioSRAX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,010,700$20,000,000.00$10,676$355.77+$20.00M → SRAX
2$37,424,589,019$37,403,177,570.09$11,407$389.39+$37424.58M → SRAX
3$65,416,215,188,220$65,376,170,877,969.18$12,198$426.53+$65416215.18M → SRAX
4$106,868,230,495,008,900$106,798,235,144,757,520.00$13,056$467.62+$106868230495.00M → SRAX
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$13,987$513.12+$163172871735896.88M → SRAX
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$14,998$563.56+$232854599801468864.00M → SRAX
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$16,098$619.52+$310570858137017057280.00M → SRAX
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$17,295$681.69+$3.871481543016132e+23M → SRAX
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$18,599$750.82+$4.510617497632811e+26M → SRAX
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$20,022$827.78+$4.911780474428384e+29M → SRAX

SRAX vs JNJ: Complete Analysis 2026

SRAX — Stock

SRAX, Inc., a technology company, focused on enhancing communications between public companies and their shareholders and investors in the United States. The company offers Sequire, a Saas platform that allows issuers to track their shareholders' behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels. It also organizes and hosts investor conferences within the micro and small- cap space. The company markets and sells its services through its in-house sales and marketing team. The company was formerly known as Social Reality, Inc. and changed its name to SRAX, Inc. in August 2019. SRAX, Inc. was founded in 2009 and is headquartered in Westlake Village, California.

Full SRAX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SRAX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRAX vs SCHDSRAX vs JEPISRAX vs OSRAX vs KOSRAX vs MAINSRAX vs ABBVSRAX vs MRKSRAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.